Trial intelligence / Profile preview

Phase 3 study of daclatasvir + peginterferon lambda-1a + ribavirin versus telaprevir + peginterferon alfa-2a + ribavirin in chronic hepatitis C genotype 1b

2011-005409-65Phase 3Completed

Sponsor

Bristol Myers Squibb

Start

Nov 2012

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Countries

1